Analytical Data
-
Gene name
CNR1
- Application
-
Alternative Names
CANN6; CB-R; CB1; CB1A; CB1K5; CNR
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P20272
-
Expression Region
Met1~Gln117
-
Molecular Weight
17kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CNR1, or cannabinoid receptor 1, is a G protein-coupled receptor primarily involved in the endocannabinoid system, which regulates various physiological processes including pain, mood, appetite, and memory. The receptor has garnered significant interest in biochemical and pharmacological research due to its implications in neuropsychiatric disorders and metabolic conditions. Studies have shown that CNR1 plays a crucial role in modulating synaptic transmission and plasticity, influencing how information is processed in the brain. Furthermore, the exploration of CNR1 recombination, which involves the study of its structure and function through the generation of recombinant proteins, has opened new avenues for drug development. Understanding the intricate mechanisms by which CNR1 operates at a molecular level can facilitate the identification of novel therapeutic targets for conditions such as anxiety, depression, and obesity. By utilizing recombinant technology, researchers can produce purified CNR1 proteins to investigate their interactions with potential ligands and elucidate signaling pathways, thereby advancing our comprehension of this receptor and its potential as a pharmacological target in various therapeutic contexts.
